Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Sanofi nears deal to buy Hemophilia drugmaker Bioverativ for over $11.5 bln - WSJ

1:44am GMT

Jan 21 (Reuters) - :SANOFI NEARS DEAL TO BUY HEMOPHILIA DRUGMAKER BIOVERATIV FOR MORE THAN $11.5 BILLION - WSJ, CITING SOURCES‍​.

Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer

Friday, 19 Jan 2018

Jan 19 (Reuters) - Nucana Plc ::NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER.NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES.NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN.NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018.NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.

Orexigen Therapeutics Says ‍Expect Annualized Savings Associated With Feb 2018 Reduction In Sales Force Of About $30 Mln​

Friday, 19 Jan 2018

Jan 19 (Reuters) - Orexigen Therapeutics Inc ::OREXIGEN THERAPEUTICS SAYS ‍EXPECT ANNUALIZED SAVINGS ASSOCIATED WITH FEB 2018 REDUCTION IN SALES FORCE OF ABOUT $30 MILLION​ - SEC FILING.

Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

Friday, 19 Jan 2018

Jan 19 (Reuters) - Albireo Pharma Inc ::ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS.ALBIREO PHARMA INC - ELOBIXIBAT APPROVED IN JAPAN FOR TREATMENT OF CHRONIC CONSTIPATION.ALBIREO PHARMA - JAPAN'S MINISTRY OF HEALTH, LABOR & WELFARE APPROVED NEW DRUG APPLICATION FOR ELOBIXIBAT FOR TREATMENT OF CHRONIC CONSTIPATION IN JAPAN.ALBIREO PHARMA INC - APPROVAL OF ELOBIXIBAT IN JAPAN TRIGGERS PAYMENTS TO ALBIREO SUBSIDIARY ELOBIX AB FROM EA PHARMA CO LTD.ALBIREO PHARMA - CO ‍EXPECTS TO INITIATE A PLANNED PHASE 3 STUDY OF A4250 BY SPRING OF 2018​.

Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017

Friday, 19 Jan 2018

Jan 19 (Reuters) - Bradley Thomas Sorenson: :BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING.BRADLEY THOMAS SORENSON - PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".

Sangui Biotech: Revenues Of $54,000 In H1

Friday, 19 Jan 2018

Jan 19 (Reuters) - SANGUI BIOTECH INTERNATIONAL INC ::DGAP-NEWS: SANGUI BIOTECH INTERNATIONAL INC.: - REVENUES OF USD 54,000 IN THE FIRST HALF-YEAR; GRANULOX LICENSE INCOME INCREASED BY 54%..REVENUES OF USD 54,000 IN FIRST HALF-YEAR;.

Cantargia: European Patent For Solid Tumours Remains In Force

Friday, 19 Jan 2018

Jan 19 (Reuters) - CANTARGIA AB ::CANTARGIA'S EUROPEAN PATENT FOR SOLID TUMOURS REMAINS IN FORCE.‍EPO HAS REJECTED OPPOSITION AND CANTARGIA'S PATENT IS THUS MAINTAINED WITH UNCHANGED CLAIMS​.

Phaserx Revokes Proposed Distribution Record Date

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Phaserx Inc ::PHASERX- REVOKED PROPOSED DISTRIBUTION RECORD DATE AS REQUESTED IN DISTRIBUTION RECORD DATE MOTION, WITHDREW THE MOTION IN BANKRUPTCY COURT-SEC FILING.

FIT Biotech Appoints Erkki Pekkarinen New CEO

Thursday, 18 Jan 2018

Jan 18 (Reuters) - FIT BIOTECH OY ::REG-FIT BIOTECH OY: FIT BIOTECH'S CEO TO CHANGE - ERKKI PEKKARINEN APPOINTED AS A NEW CEO.‍CURRENT CHIEF EXECUTIVE OFFICER JAMES KUO LEAVES HIS POST IMMEDIATELY.​.

Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

Thursday, 18 Jan 2018

Jan 18 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $5.25PER SHARE.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary